ARMAS Pharmaceuticals Logo
  • About Us
    • Overview
    • Partnerships
    • Careers
  • Products
  • News
  • Contact

Armas Pharmaceuticals Announces the Reintroduction of Lidocaine Jelly 2% 30mL to the U.S. Market

FREEHOLD, N.J., March 27, 2025 /PRNewswire/ — Armas Pharmaceuticals, a leading provider of high-quality pharmaceutical products, is pleased to announce the reintroduction of Lidocaine Jelly 2% 30mL to the U.S. market. This key product has been unavailable for...

Armas Pharmaceuticals and Steriscience Enter Strategic Partnership to Commercialize Products for the U.S. Market

Armas Pharmaceuticals, Inc. and Steriscience have today announced an exclusive partnership for the distribution and supply of products for the U.S. market. In the first full year of collaboration, Steriscience intends to launch up to eight products through Armas...

Armas Pharmaceuticals Adds Four Generic Injectables As First Launches of 2020

Armas Pharmaceuticals Inc. (Armas), has begun the new year with launches of four generic injectables: Caffeine Citrate, Docetaxel, Gemcitabine and Verapamil HCI. These products are now a part of Armas’ consistently growing product line, bringing their portfolio...

Armas Pharmaceuticals Announces Launch of Oncology Generic Erlotinib

Armas Pharmaceuticals Inc. (Armas) is announcing the launch of generic Tarceva® (a trademark of Genentech USA, Inc) Tablets. Erlotinib is now available in 25mg, 100mg and 150mg strengths. This is Armas’ third oral solid to be added to their oncology portfolio....

Armas and Micro Labs Announce Collaboration To Launch Generic Injectables to U.S. Market

Armas Pharmaceuticals Inc. and Micro Labs USA, Inc. have announced today, the forming of a strategic collaboration to bring select multisource injectable products to the U.S. market. The first product, Diphenhydramine Injection 50mg/1mL, is slated to be launched in...

Recent Posts

  • Armas Pharmaceuticals Announces the Reintroduction of Lidocaine Jelly 2% 30mL to the U.S. Market
  • Armas Pharmaceuticals and Steriscience Enter Strategic Partnership to Commercialize Products for the U.S. Market
  • Armas Pharmaceuticals Adds Four Generic Injectables As First Launches of 2020
  • Armas Pharmaceuticals Announces Launch of Oncology Generic Erlotinib
  • Armas and Micro Labs Announce Collaboration To Launch Generic Injectables to U.S. Market

Armas Pharmaceuticals, Inc.

We are interested in exploring partnerships and/or licensing agreements within the industry to support its growing pipeline of products.

Contact Us

PHONE: 732.637.1971

  • Follow

About Us     Products     News     Contact     Privacy Policy

© 2025 Armas Pharmaceuticals, Inc.